$1.67 Billion is the total value of Consonance Capital Management LP's 32 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 240.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRSN | New | MERSANA THERAPEUTICS INC | $137,974,000 | – | 5,896,326 | +100.0% | 8.27% | – |
| MGNX | New | MACROGENICS INC | $112,840,000 | – | 4,041,535 | +100.0% | 6.76% | – |
| GNMK | New | GENMARK DIAGNOSTICS INC | $101,418,000 | – | 6,894,481 | +100.0% | 6.08% | – |
| KDMN | Buy | KADMON HLDGS INC | $80,438,000 | +23.0% | 15,710,548 | +0.7% | 4.82% | -1.0% |
| ATRA | New | ATARA BIOTHERAPEUTICS INC | $76,321,000 | – | 5,238,218 | +100.0% | 4.57% | – |
| KNSA | Buy | KINIKSA PHARMACEUTICALS LTD | $72,449,000 | +108.9% | 2,843,384 | +26.9% | 4.34% | +68.1% |
| CGEN | New | COMPUGEN LTDord | $61,243,000 | – | 4,077,421 | +100.0% | 3.67% | – |
| APRE | New | APREA THERAPEUTICS INC | $48,560,000 | – | 1,252,185 | +100.0% | 2.91% | – |
| Buy | APTOSE BIOSCIENCES INC | $43,980,000 | +27.7% | 6,969,904 | +20.2% | 2.64% | +2.8% | |
| ISEE | Buy | IVERIC BIO INC | $23,718,000 | +118.8% | 4,650,565 | +47.6% | 1.42% | +76.1% |
| BLU | Buy | BELLUS HEALTH INC NEW | $19,783,000 | +24.1% | 1,922,503 | +20.3% | 1.19% | -0.1% |
| STXS | New | STEREOTAXIS INC | $16,317,000 | – | 3,658,537 | +100.0% | 0.98% | – |
| HARP | New | HARPOON THERAPEUTICS INC | $14,013,000 | – | 844,162 | +100.0% | 0.84% | – |
| ATNM | New | ACTINIUM PHARMACEUTICALS INC | $13,006,000 | – | 37,000,000 | +100.0% | 0.78% | – |
| ARAV | New | ARAVIVE INC | $11,226,000 | – | 964,456 | +100.0% | 0.67% | – |
| SLNO | New | SOLENO THERAPEUTICS INC | $6,749,000 | – | 3,040,000 | +100.0% | 0.40% | – |
| SILK | New | SILK RD MED INC | $209,000 | – | 5,000 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.